Comparison between 5-day aprepitant and single-dose fosaprepitant meglumine for preventing nausea and vomiting induced by cisplatin-based chemotherapy

• Published in: Supportive care in cancer 2016-02, Vol.24 (2), p.871-878
• Main Authors: Ando, Yosuke, Hayashi, Takahiro, Ito, Kaori, Suzuki, Eri, Mine, Naoyuki, Miyamoto, Ayumi, Oya, Miyuki, Matsuda, Hidezo, Isaji, Ami, Nakanishi, Toru, Imaizumi, Kazuyoshi, Shibata, Tomoyuki, Okada, Tatsuyoshi, Sakurai, Kazuo, Naito, Kensei, Uyama, Ichiro, Kawada, Kenji, Takahashi, Hiroshi, Yamada, Shigeki
• Format: Article
• Language: English
• Subjects: Aged; Analysis; Antiemetics - therapeutic use; Antineoplastic agents; Chemotherapy; Cisplatin - adverse effects; Cisplatin - therapeutic use; Dosage and administration; Esophageal cancer; Esophageal Neoplasms - drug therapy; Female; Head and Neck Neoplasms - drug therapy; Humans; Lung cancer; Lung Neoplasms - drug therapy; Male; Medicine; Medicine & Public Health; Meglumine; Middle Aged; Morpholines - therapeutic use; Nausea; Nausea - chemically induced; Nausea - drug therapy; Nausea - prevention & control; Nursing; Nursing Research; Oncology; Original; Original Article; Pain Medicine; Rehabilitation Medicine; Risk Factors; Side effects; Stomach cancer; Stomach Neoplasms - drug therapy; Surveys and Questionnaires; Treatment Outcome; Vomiting; Vomiting - chemically induced; Vomiting - drug therapy; Vomiting - prevention & control
• ISSN: 0941-4355; 1433-7339
• DOI: 10.1007/s00520-015-2856-9

Purpose We aimed to compare the preventive effect of 5-day administration of aprepitant with single administration of fosaprepitant meglumine against nausea and vomiting symptoms due to highly emetogenic chemotherapy regimens comprising cisplatin (CDDP). Methods Subjects were inpatients who underwent chemotherapy for gastric cancer, esophageal cancer, lung cancer, or head and neck cancer with a regimen comprising 60 mg/m 2 or higher dose of CDDP. In this randomised, open-label, controlled study, the subjects were assigned to a group given aprepitant for 5 days or a group given a single administration of fosaprepitant meglumine. The nausea and vomiting symptoms that emerged within 7 days after the first CDDP administration were investigated with a questionnaire form; the results were compared between the two groups. Risk factors affecting nausea and vomiting symptoms were also investigated. Results Of the 101 patients enrolled, 93 patients were included (48 in the 5-day aprepitant group and 45 in the single fosaprepitant meglumine group). No significant intergroup differences in the complete response rate or the complete control rate were found over the entire period. The nausea score tended to increase from day 3 in both groups, but no significant intergroup difference was observed. Furthermore, the investigation of risk factors affecting moderate or severe nausea symptoms indicated that the fosaprepitant meglumine administration was not a risk factor. Conclusions Single administration of fosaprepitant meglumine was not inferior to 5-day administration of aprepitant for preventing acute and delayed nausea and vomiting symptoms occurring after administration of CDDP (60 mg/m 2 or higher).